Similar articles

• YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

  Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, Kudoh M, Sasamata M. Nakahara T, et al. Cancer Res. 2007 Sep 1;67(17):8014-21. doi: 10.1158/0008-5472.CAN-07-1343. Cancer Res. 2007. PMID: 17804712
• Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.

  Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K, Nakagawa K. Iwasa T, et al. Clin Cancer Res. 2008 Oct 15;14(20):6496-504. doi: 10.1158/1078-0432.CCR-08-0468. Clin Cancer Res. 2008. PMID: 18927289
• A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma.

  Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E, Gonzalez R. Lewis KD, et al. Invest New Drugs. 2011 Feb;29(1):161-6. doi: 10.1007/s10637-009-9333-6. Epub 2009 Oct 15. Invest New Drugs. 2011. PMID: 19830389 Clinical Trial.
• [Survivin in cancerology : molecular aspects and therapeutic applications].

  Romagnoli M, Séveno C, Bataille R, Barillé-Nion S. Romagnoli M, et al. Med Sci (Paris). 2008 Oct;24(10):821-7. doi: 10.1051/medsci/20082410821. Med Sci (Paris). 2008. PMID: 18950577 Review. French.
• Survivin and YM155: how faithful is the liaison?

  Rauch A, Hennig D, Schäfer C, Wirth M, Marx C, Heinzel T, Schneider G, Krämer OH. Rauch A, et al. Biochim Biophys Acta. 2014 Apr;1845(2):202-20. doi: 10.1016/j.bbcan.2014.01.003. Epub 2014 Jan 16. Biochim Biophys Acta. 2014. PMID: 24440709 Review.